Clinical trials: Hepatitis A
Chronic Hepatitis B
Switch or Sequential Combination Therapy of Peginterferon in Hepatitis B Patients With Longterm Entecavir Therapy
This is a multicenter, prospective cohort study to evaluate the efficacy and safety of sequential combination or switch therapy of pegylated interferon alfa-2a in chronic hepatitis B patients with low HBsAg and HBeAg titers after…
- Trial name
- NCT02589652
- Testing
- Pegylated interferon alfa-2a, Pegylated interferon alfa-2a plus Entecavir, Entecavir
- Where
- 17 sites in China
- Volunteers
- 294 people
- Sponsor
- Huashan Hospital
Hepatitis
S-Adenosylmethionine Therapy for Non-Alcoholic Steatohepatitis
The purpose of this study is to examine the effect of S-adenosylmethionine therapy in those patients with non-alcoholic liver disease in the form of steatohepatitis (NASH).
- Trial name
- NCT00108589
- Testing
- S-adenosylmethionine
- Where
- United States
- Sponsor
- US Department of Veterans Affairs
Hepatitis B, Chronic
A Study of Peginterferon Alfa-2a [PEGASYS] in Patients With Chronic Hepatitis B Who Are HBeAg Positive
This open-label, multi-center study will evaluate the effect on the quantitative HBsAg reduction of peginterferon alfa-2a [PEGASYS] in patients with HBeAg positive chronic hepatitis B.
- Trial name
- NCT01086085
- Testing
- Adefovir, peginterferon alfa-2a [PEGASYS]
- Where
- 11 sites in China
- Volunteers
- 265 people
- Sponsor
- Hoffmann-La Roche
HCV
A Clinical Trial of 16 Weeks of Duration to Evaluate Retreatment With Elbasvir/Grazoprevir Plus Sofosbuvir and Ribavirin in Patients With Chronic Hepatitis C Genotypes 1,4 Who Have Failed to Treat With a Regime Based on an Inhibitor of the NS5A
This is a phase 4 clinical trial to treat patients who have failed to treat with regimen based on an inhibitor of the NS5A
- Trial name
- C-RESCUE (NCT03105349)
- Testing
- elbasvir/grazoprevir, Sofosbuvir, Ribavirin
- Where
- 5 sites in Spain
- Sponsor
- Fundacion SEIMC-GESIDA
Hepatitis C Virus
Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
The purpose of this study is to evaluate the efficacy of 6 or 8 weeks of treatment regimen containing simeprevir (SMV), daclatasvir (DCV) and sofosbuvir (SOF) in treatment-naive (not having received treatment with any approved or…
- Trial name
- ACCORDION-1 (NCT02349048)
- Testing
- Simeprevir 150 mg, Daclatasvir 60 mg, Sofosbuvir 400 mg
- Where
- 8 sites in United States, Canada
- Volunteers
- 68 people
- Sponsor
- Janssen Research & Development, LLC
HIV, Hepatitis C
Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection
HIV infection exerts a negative impact on the course of HCV infection. Co-infected individuals progress more rapidly to liver fibrosis, cirrhosis and ESLD compared to those infected with HCV alone.
- Conditions
- HIV, Hepatitis C, Liver Fibrosis
- Trial name
- NCT01231685
- Testing
- Raltegravir, Ritonavir-boosted protease inhibitor
- Where
- 3 sites in Canada
- Volunteers
- 9 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
HIV, Hepatitis C
Drug Interaction Potential Between Dolutegravir and Simeprevir in HIV/HCV Seronegative Volunteers
The investigator believes simeprevir concentrations are unchanged when administered in combination with dolutegravir relative to administration alone.
- Trial name
- NCT02404805
- Testing
- dolutegravir, simeprevir
- Where
- United States
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- University of Colorado, Denver
Hepatitis B Virus Infection; Pregnant Women
TAF vs TDF During the Pregancy
The goal of this clinical trial is to learn the efficacy and safety of Tenofovir alafenamide (TAF) vs Tenofovir disoproxil fumarate(TDF) in early and middle pregnancy antiviral therapy for chronic hepatitis B pregnant women.
- Trial name
- TAF；TDF；RCT (NCT07542951)
- Testing
- TAF
- Where
- China
- Volunteers
- 210 people
- Sponsor
- The Third Affiliated Hospital of Guangzhou Medical University
Hepatitis C, Chronic
A Study of Combination Treatment With Pegasys (Peginterferon Alfa) and Copegus (Ribavirin)in Patients With Chronic Hepatitis C
This 2 arm open-label study will assess the safety and tolerability of combination treatment with Peginterferon alfa (Pegasys) and Ribavirin (Copegus) in patients with chronic hepatitis C.
- Trial name
- NCT00940420
- Testing
- Copegus (ribavirin), peginterferon alfa-2a [Pegasys]
- Where
- 20 sites in Israel
- Volunteers
- 2,695 people
- Sponsor
- Hoffmann-La Roche
Hepatitis B, Chronic
Evaluate the Efficacy and Safety of HLX10 in Chronic Hepatitis B Patients
A multiple-center, open-label, Phase II clinical trial to evaluate the safety and the efficacy of HLX10 in chronic hepatitis B patients.
- Trial name
- NCT04133259
- Testing
- Recombinant anti-programmed death-1 (PD-1) humanized monoclonal antibody, Nucleoside/nucleotide analogues
- Where
- 3 sites in Taiwan
- Volunteers
- 44 people
- Sponsor
- Henlix, Inc
Hepatitis B, Hepatitis C
Hepatitis B Virus (HBV) Prevention for Homeless at Risk for HBV/Hepatitis C Virus (HCV)/HIV
In this study, researchers from UCLA and Friends Community Center will work together in designing a program to assist young homeless stimulant-using gay and bisexual homeless men to complete the hepatitis vaccine and in reducing…
- Conditions
- Hepatitis B, Hepatitis C, HIV, HIV Infections
- Trial name
- HBV (NCT00926146)
- Testing
- NCMIT, SCMIT
- Where
- United States
- Volunteers
- 451 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
ESRD, Hepatitis C
Live Kidney Donors With Positive Anti-HCV Antibody, But Negative HCV PCR
It is well recognized that a subset of patients who contracts Hepatitis C virus (HCV) spontaneously clears the virus. Such individuals are anti-HCV antibody positive, yet HCV RNA PCR negative in the blood.
- Trial name
- NCT02669966
- Testing
- Kidney transplantation
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Florida
Chronic Hepatitis B, Alcoholic Hepatitis
Alcohol Consumption and Plasma cfDNA Methylation in Chronic Hepatitis B
This is an observational, exploratory study designed to investigate the effect of different levels of alcohol consumption on plasma cell-free DNA (cfDNA) methylation profiles in participants with chronic hepatitis B.
- Trial name
- NCT07865520
- Testing
- Alcohol Consumption
- Where
- China
- Volunteers
- 85 people
- Sponsor
- Beijing Municipal Administration of Hospitals
Hepatitis A Vaccine
This Study Will Evaluate the Persistence of Hepatitis A Antibodies, 8 Years and 10 Years Later, in Children Who Had Received Havrix at Selected Health Centres of Panama
The purpose of this study is to evaluate the persistence of hepatitis A antibodies, approximately 8 years and 10 years post vaccination with the complete series of Havrix (2 doses) and the partial series completion (1 dose).
- Trial name
- NCT02712359
- Testing
- Blood sample collection
- Where
- 3 sites in Panama
- Volunteers
- 1,201 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C
Proof of Concept Study to Determine the Safety and Antiviral Effect of BZF961 With or Without Ritonavir Boosting in Hepatitis C Virus Infected Patients
To evaluate the antiviral activity of 3 days of BZF961. To determine safety and tolerability of BZF961 in HCV patients. To evaluate pharmacokinetics of BZF961 in HCV patients.
- Trial name
- CBZF961X2201 (NCT01825980)
- Testing
- BZF961, Ritonavir
- Where
- 3 sites in United States
- Volunteers
- 54 people
- Sponsor
- Novartis Pharmaceuticals
Hepatitis B, Portal Hypertension
Atorvastatin Use and Portal Hypertension in Patients With Hepatitis B Virus-related Liver Cirrhosis: A Randomized Controlled Trial
To evaluate whether atorvastatin can improve portal hypertension in patients with chronic hepatitis B related compensated cirrhosis with portal hypertension
- Trial name
- STAPH (NCT05483894)
- Testing
- Atorvastatin 10mg
- Volunteers
- 36 people
- Sponsor
- Samsung Medical Center
Opioid Use Disorder, HIV
Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans
Opioid use disorder (OUD) confers a higher risk of acquiring and transmitting infectious diseases, which may have long-term health consequences in Veterans.
- Conditions
- Opioid Use Disorder, HIV, Hepatitis C Virus, Gonorrhea
- Trial name
- NCT06766331
- Testing
- Integrated care
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Chronic Hepatitis C (Disorder)
Dynamic Changes of Monocytes and NK Cells of CHC Patient Treated by DAAs
Recently,surprisingly and unexpectedly increased aggressiveness and high rates of HCC recurrence (28%(16/58) and 29%(17/59), respectively) have been reported in patients who cleared HCV with DAAs after achieving a complete…
- Trial name
- NCT03063723
- Testing
- Ledipasvir-Sofosbuvir, Daclatasvir-Sofosbuvir
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Third Affiliated Hospital, Sun Yat-Sen University
Hepatitis
The Curative Effect of Entecavir Combined Resveratrol on HBV patients-a Multi-center, Random, Open Clinical Trial
The purpose of this study is to use entecavir combined with other drug such as resveratrol and thymosin to treat patients with hepatitis B, which may provide a novel therapy target hepatitis B.
- Trial name
- NCT03509688
- Testing
- entecavir+resveratrol, Entecavir, entecavir+thymosin α1
- Volunteers
- 312 people
- Sponsor
- The First Hospital of Jilin University
Hepatitis C, Chronic
The No One Waits Study: Acceptability and Feasibility of Community-based Point-of-diagnosis HCV Treatment Study
Direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) offers a cure to those with chronic HCV infection. For marginalized communities, linkage to care services often aren't enough to overcome barriers to accessing the…
- Trial name
- NOW (NCT03987503)
- Testing
- Epclusa (SOF/VEL), Standard of care, Fibroscan® 430 Mini Plus
- Where
- United States
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco